Replies to post #21727 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Neuro - do you have a sense of what level of interest the RD results have generated amongst potential partners?

Are the POC results Cortex now has really strong enough to "force" the companies with affected pain medicine franchises to seriously consider Ampakines as either a threat or an opportunity?

[jerrydylan]

the chart is pathetic- like some well I won't say, the overall market worse. If a BP wanted in I'd just make an offer of $2 and see what happens. It was better before all the RD data, which makes no sense...but then US Steel @ $195 made no sense either.

[bladerunner1717]

Neuro,

I think another trend should be noted--and maybe you saw some evidence of it at the conference???--and that is the tendency of BP to "outsource" it's R&D. The shrinking pipelines and the shrinking R&D resources at BP might give reason to be a little more optimistic in this terrible environment.


Bladerunner